LRMR
NASDAQ · Biotechnology
Larimar Therapeutics Inc
$4.25
-0.02 (-0.47%)
Open$4.25
Previous Close$4.27
Day High$4.27
Day Low$4.17
52W High$6.42
52W Low$2.72
Volume—
Avg Volume1.19M
Market Cap445.14M
P/E Ratio—
EPS$-1.99
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+447.5% upside
Current
$4.25
$4.25
Target
$23.27
$23.27
$16.60
$23.27 avg
$30.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 175.11M | 171.92M | 184.32M |
| Net Income | -19,494,630 | -18,016,562 | -21,970,966 |
| Profit Margin | -11.1% | -10.5% | -11.9% |
| EBITDA | -28,814,403 | -28,168,357 | -29,490,113 |
| Free Cash Flow | -20,989,250 | -18,411,143 | -19,560,158 |
| Rev Growth | -5.1% | +17.2% | +14.9% |
| Debt/Equity | 0.69 | 0.58 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |